非重症COVID-19与内皮损伤及高凝状态相关,尽管已接受药物血栓预防
本研究比较中等 severity COVID-19 住院患者与非 COVID-19 住院患者,均接受标准强度低分子量肝素血栓预防。结果显示 COVID-19 组组织型纤溶酶原激活物水平和内源性凝血酶生成潜力显著升高,滞后时间延长,提示高凝状态持续存在。
要点
- 中等 severity COVID-19 患者接受标准低分子量肝素预防后仍存在高凝状态。
- COVID-19 组组织型纤溶酶原激活物水平显著高于非 COVID-19 住院患者。
- 内源性凝血酶生成潜力显著增加,但凝血酶生成滞后时间显著延长。
核心结论
- 中等 severity COVID-19 与血浆凝血酶生成增加和内皮损伤相关,且高凝状态在标准低分子量肝素血栓预防下持续存在。
研究设计与样本
- 研究纳入中等 severity COVID-19 患者和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)阴性住院患者作为对照组,两组均接受低分子量肝素血栓预防,评估内皮损伤标志物和血浆凝血酶生成参数。
主要发现
- COVID-19 组组织型纤溶酶原激活物水平为 8.3 ± 4.4 ng/ml,对照组为 4.9 ± 2.4 ng/ml,COVID-19 组显著升高(P = .02)。
- COVID-19 组平均内源性凝血酶生成潜力为 1929 ± 448 nM*min,对照组为 1528 ± 460.8 nM*min,COVID-19 组显著升高(P = .04)。
- COVID-19 组凝血酶生成滞后时间为 8.1 ± 1.8 分钟,对照组为 6.2 ± 1.8 分钟,COVID-19 组显著延长(P = .02)。
- 两组组织因子途径抑制物(TFPI)水平相似;在加入抑制性抗 TFPI 抗体后,两组间滞后时间差异消失。
临床怎么用
- 作者认为,鉴于近期临床试验数据提示非重症 COVID-19 中升级肝素剂量可能与改善临床结局相关,这些发现可能具有临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypercoagulability and endothelial dysfunction are hallmarks of coronavirus disease 2019 (COVID-19) and appear to predict disease severity. A high incidence of thrombosis despite thromboprophylaxis is reported in patients with moderate to severe COVID-19. Recent randomized clinical trials suggest that therapeutic-intensity heparin confers a survival benefit in moderate-severity COVID-19 compared to standard-intensity heparin, potentially by harnessing heparin-mediated endothelial-stabilizing and anti-inflammatory effects. OBJECTIVE: We hypothesized that patients with moderate-severity COVID-19 exhibit enhanced hypercoagulability despite standard-intensity thromboprophylaxis with low molecular weight heparin (LMWH) compared to non-COVID-19 hospitalized patients. METHODS: Patients with moderate COVID-19 and a control group (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-negative hospitalized patients) receiving LMWH thromboprophylaxis were recruited. Markers of endothelial damage and plasma thrombin generation parameters were assessed. RESULTS: Tissue plasminogen activator levels were significantly increased in the COVID-19 group (8.3 ± 4.4 vs. 4.9 ± 2.4 ng/ml; P = .02) compared to non-COVID-19-hospitalized patients. Despite thromboprophylaxis, mean endogenous thrombin potential was significantly increased among COVID-19 patients (1929 ± 448 vs. 1528 ± 460.8 nM*min; P = .04) but lag time to thrombin generation was significantly prolonged (8.1 ± 1.8 vs. 6.2 ± 1.8 mins; P = .02). While tissue factor pathway inhibitor (TFPI) levels were similar in both groups, in the presence of an inhibitory anti-TFPI antibody, the difference in lag time between the groups was abrogated. CONCLUSIONS: Collectively, these data demonstrate that COVID-19 of moderate severity is associated with increased plasma thrombin generation and endothelial damage, and that hypercoagulability persists despite standard LMWH thromboprophylaxis. These findings may be of clinical interest given recent clinical trial data which suggest escalated heparin dosing in non-severe COVID-19 may be associated with improved clinical outcomes.
引用
- Kelliher S, Weiss L, Cullivan S, et al. Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. J Thromb Haemost. 2022. PMID: 35102689. doi:10.1111/jth.15660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。